Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation

International Journal of Andrology

Volumn 33, Issue 6, 2010, Pages 784-793

  Marchiani, S ^a   Tamburrino, L ^a   Nesi, G ^a   Paglierani, M ^a   Gelmini, S ^a   Orlando, C ^a   Maggi, M ^a   Forti, G ^a   Baldi, E ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Androgen receptor; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR; GEFITINIB; MESSENGER RNA; NEURON SPECIFIC ENOLASE; SOMATOSTATIN RECEPTOR; THAPSIGARGIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; CELL DIFFERENTIATION; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; NEUROENDOCRINE CELLS; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN;

EID: 78650491839     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2009.01030.x     Document Type: Article

References (45)

1. Abrahamsson, P. A. & Lilja, H. (1989) Partial characterization of a thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 14, 71-81.
2. Adam, R. M., Kim, J., Lin, J., Orsola, A., Zhuang, L., Rice, D. C. & Freeman, M. R. (2002) Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143, 4599-4608.
3. Arnold, J. T. & Isaacs, J. T. (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9, 61-73.
4. Balk, S. P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-138.
5. Van Bokhoven, A., Varella-Garcia, M., Korch, C., Johannes, W. U., Smith, E. E., Miller, H. L., Nordeen, S. K., Miller, G. J. & Lucia, M. S. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205-225.
6. Bonaccorsi, L., Carloni, V., Muratori, M., Salvatori, A., Giannini, A., Carini, M., Serio, M., Forti, G. & Baldi, E. (2000) Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 141, 3172-3182.
7. Bonaccorsi, L., Carloni, V., Muratori, M., Formigli, L., Zecchi, S., Forti, G. & Baldi, E. (2004a) EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 112, 78-86.
8. Bonaccorsi, L., Marchiani, S., Muratori, M., Forti, G. & Baldi, E. (2004b) Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J Cancer Res Clin Oncol 130, 604-614.
9. Bonaccorsi, L., Nosi, D., Muratori, M., Formigli, L., Forti, G. & Baldi, E. (2007) Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38, 51-66.
10. Canil, C. M., Moore, M. J., Winquist, E., Baetz, T., Pollak, M., Chi, K. N. et al. (2005) Randomized phase II study of two doses of gefinitib in hormone refractory prostate cancer: a trial of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 23, 455-460.
11. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G. & Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39.
12. Craft, N., Chhor, C., Tran, C., Belldegrun, A., DeKernion, J., Witte, O. N., Said, J., Reiter, R. E. & Sawyers, C. L. (1999) Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59, 5030-5036.
13. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68, 5469-5477.
14. Dizeyi, N., Konrad, L., Bjartell, A., Wu, H., Gadaleanu, V., Hansson, J., Helboe, L. & Abrahamsson, P. A. (2002) Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7, 91-98.
15. Espey, D. K., Wu, X. C., Swan, J., Wiggins, C., Jim, M. A., Ward, E. et al. (2007) Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110, 2119-2152.
16. Fixemer, T., Remberger, K. & Bonkhoff, H. (2002) Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53, 118-123.
17. He, Q., Lee, D. I., Rong, R., Yu, M., Luo, X., Klein, M., El-Deiry, W. S., Huang, Y., Hussain, A. & Sheikh, M. S. (2002) Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 21, 2623-2633.
18. Higashiyama, S., Iwabuki, H., Morimoto, C., Hieda, M., Inoue, H. & Matsushita, N. (2008) Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 99, 214-220.
19. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A. & Murphy, G. P. (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-1818.
20. Humez, S., Monet, M., Legrand, G., Lepage, G., Delcourt, P. & Prevarskaya, N. (2006) Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 13, 181-195.
21. Jongsma, J., Oomen, M. H., Noordzij, M. A., Van Weerden, W. M., Martens, G. J., Van Der Kwast, T. H., Schröder, F. H. & Van Steenbrugge, G. J. (2000) Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60, 741-748.
22. Kim, J., Adam, R. M. & Freeman, M. R. (2002) Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 62, 1549-1554.
23. Komiya, A., Suzuki, H., Imamoto, T., Kamiya, N., Nihei, N., Naya, Y., Ichikawa, T. & Fuse, H. (2009) Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 16, 37-44.
24. Li, Y., Chen, H. Q., Chen, M. F., Liu, H. Z., Dai, Y. Q., Lv, H., Bing Zu, X. & Qi, L. (2009) Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Science 84, 822-827.
25. -ΔΔCt method. Methods 25, 402-408.
26. Luciani, P., Gelmini, S., Ferrante, E., Lania, A., Benvenuti, S., Baglioni, S. et al. (2005) Expression of the antiapoptotic gene Seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 90, 6156-6161.
27. Marchiani, S., Bonaccorsi, L., Ferruzzi, P., Crescioli, C., Muratori, M., Adorini, L., Forti, G., Maggi, M. & Baldi, E. (2006) The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 132, 408-416.
28. Martinez, H. D., Jasavala, R. J., Hinkson, I., Fitzgerald, L. D., Trimmer, J. S., Kung, H. J. & Wright, M. E. (2008) RNA editing of androgen receptor gene transcripts in prostate cancer cells. J Biol Chem 283, 29938-29949.
29. Martín-Orozco, R. M., Almaraz-Pro, C., Rodríguez-Ubreva, F. J., Cortés, M. A., Ropero, S., Colomer, R., López-Ruiz, P. & Colás, B. (2007) EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia 9, 614-624.
30. Montironi, R., Cheng, L., Mazzucchelli, R., Morichetti, D., Stramazzotti, D., Santinelli, A. et al. (2008) Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction. Cell Oncol 30, 473-482.
31. Nelson, E. C., Cambio, A. J., Yang, J. C., Ok, J. H., Lara, P. N. Jr & Evans, C. P. (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer and Prostatic Dis 10, 6-14.
32. Pignon, J. C., Koopmansch, B., Nolens, G., Delacroix, L., Waltregny, D. & Winkler, R. (2009) Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res 69, 2941-2949.
33. Pytel, D., Sliwinski, T., Poplawski, T., Ferriola, D. & Majsterek, I. (2009) Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 9, 66-76.
34. Reubi, J. C., Waser, B., Schaer, J. C. & Markwalder, R. (1995) Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 80, 2806-2814.
35. Sant'Agnese, P. A. & Cockett, A. T. (1994) The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 152, 1927-1931.
36. Soldani, C. & Scovassi, A. I. (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7, 321-328.
37. Sramkoski, R. M., Pretlow, T. G. II, Giaconia, J. M., Pretlow, T. P., Schwartz, S., Sy, M. S., Marengo, S. R., Rhim, J. S., Zhang, D. & Jacobbereger, J. W. (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
38. Volante, M., Rosas, R., Allia, E., Granata, R., Baragli, A., Muccioli, G. & Papotti, M. (2008) Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 286, 219-229.
39. Wright, M. E., Tsai, M. J. & Aebersold, R. (2003) Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17, 1726-1737.
40. Yuan, T. C., Veeramani, S., Lin, F. F., Kondrikou, D., Zelivianski, S., Igawa, T., Karan, D., Batra, S. K. & Lin, M. F. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13, 151-167.
41. Yuan, T. C., Veeramani, S. & Lin, M. F. (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14, 531-547.
42. Zelivianski, S., Verni, M., Moore, C., Kondrikov, D., Taylor, R. & Lin, M. F. (2001) Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 1539, 28-43.
43. Zhang, X. Q., Kondrikov, D., Yuan T, C., Lin, F. F., Hansen, J. & Lin, M. F. (2003) Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 22, 6704-6716.
44. Zhou, J. R., Yu, L., Zerbini, L. F., Libermann, T. A. & Blackburn, G. L. (2004) Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 110, 800-806.
45. Zunino, F. & Pratesi, G. (2004) Camptothecins in clinical development. Expert Opin Investig Drugs 13, 269-284.